Results Overview
Overview
- We designed and constructed plasmids for E. coli Nissle 1917 Δclb to produce and secrete the anti-cancer peptide azurin in an oscillatory manner by using a repressilator
- We demonstrated that the repressilator works in our chosen chassis
- We demonstrated that the azurin is produced and also secreted
- We characterized the effect of anti-cancer drugs on colorectal cancerous Caco-2 cells
- We assembled a kill switch so that our engineered bacteria will not survive outside the patient's gut
Repressilator
Overview
Chronotherapy is a promising novel approach to treat cancer. Studies suggest that administration of anti-cancer drugs at a certain point of the circadian rhythm has a positive impact on the treatment efficiency and can lower side effects. We aim to combine E. coli Nissle 1917 Δclb bacteria‐assisted tumor‐targeted therapy with chronotherapy to explore a new method of fighting cancer. The oscillatory release of the anti-cancer drug is achieved by using a synthetic oscillatory circuit called the “repressilator”.
Key Achievements
- We tested an established repressilator system and modified it with our gene of interest
- We established and optimized a protocol that allowed us to detect oscillations by the repressilator in a plate reader assay
Azurin secretion
Overview
Azurin is a copper-binding redox protein originally found in Pseudomonas aeruginosa. In P. aeruginosa, azurin is exported into the periplasm. Azurin reduces the growth of human breast cancer and melanoma tissue with minimal side-effects. Moreover, it can be produced in E. coli. To make azurin an effective drug it needs to be secreted outside the bacterial cell in the vicinity of the colorectal tumor. Therefore, we used E. coli Nissle 1917 Δclb as our chassis and engineered the azurin gene so it can be secreted.
Key Achievements
- We added either pelB-5D or NSP4 secretion tags to the azurin and showed that the expression and secretion of azurin by our designed bacteria
- We inserted the azurin with either peIB-5D or NSP4 secretion tags into the sponge plasmid of the repressilator
MTT assay
Overview
The effectiveness of azurin against cancer cells has only been tested on breast tumors and melanoma up to now. Azurin showed significant effects on these kinds of cancer because it can amplify the effect of p53, an intracellular protein which acts as a pro-apoptosis factor. However, the effects of azurin on colorectal cancer cells are still unknown. The susceptibility of the colorectal cancer cell line called Caco-2 to different anti-cancer drugs was characterized for the first time in the iGEM competition.
Key Achievements
- We tested different concentrations of anisomycin, cisplatin, doxorubicin, salirasib and TNFa on Caco-2 cells
- We applied purified azurin on Caco-2 cells, but azurin does not have an effect on the Caco-2 cell viability at the tested concentration (Figure 2A)
Kill switch
Overview
To prevent the survival of the GMOs in the environment and in the patient's body outside the colon, we designed a kill switch. The kill switch prevents undesired survival of our chassis by killing it with a toxin/antitoxin system at two conditions: when the temperature is lower than 37°C (body temperature) and when the phosphate concentration is too high (conditions of the bloodstream). Moreover, the kill switch is intended to act as an addiction module that allows us to maintain our plasmids without the need of antibiotic resistance genes within the patient’s gut.
Key Achievements
- We assembled a multi-responsive sensor: it reacts on temperature and phosphate concentration
- we characterized the toxin-antitoxin systems ccdb/ccda and miniColicin E2/IM2 and identified the promoter induction range for differential cell growth inhibition
- We demonstrated that E. coli Nissle 1917 ΔclB has a sensitive gyrase genotype to the ccdB toxin
- We characterized our new composite part (BBa_K3482017)
- We demonstrated that our kill switch system controls cell growth effectively depending on temperature